Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: Results from a case-control study

Annals of the Rheumatic Diseases

Volumn 69, Issue 4, 2010, Pages 654-659

  Hellgren, Karin ^a   Iliadou, Anastasia ^b   Rosenquist, Richard ^c   Feltelius, Nils ^a,d   Backlin, Carin ^c   Enblad, Gunilla ^c   Askling, Johan ^a   Baecklund, Eva ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d MEDICAL PRODUCTS AGENCY   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; STEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CLASSIFICATION; CANCER RISK; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; HUMAN; INFLAMMATION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POPULATION RESEARCH; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; EPIDEMIOLOGIC METHODS; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRA-ARTICULAR; LYMPHOMA; MALE; MIDDLE AGED; SWEDEN; YOUNG ADULT;

EID: 77950329033     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.096925     Document Type: Article

References (30)

1. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007;66:1560-1567
2. Kirwan J, Power L. Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis. Curr Opin Rheumatol 2007;19:233-237
3. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006;65:285-293
4. Sørensen HT, Mellemkjaer L, Nielsen GL, et al. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004;96:709-711
5. Beiderbeck AB, Holly EA, Sturkenboom MC, et al. No increased risk of non-Hodgkin's lymphoma with steroids, estrogens and psychotropics (Netherlands). Cancer Causes Control 2003;14:639-644
6. Engels EA, Cerhan JR, Linet MS, et al. Immune-related conditions and immunemodulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. Am J Epidemiol 2005;162:1153-1161
7. Kato I, Koenig KL, Shore RE, et al. Use of anti-inflammatory and non-narcotic analgesic drugs and risk of non-Hodgkin's lymphoma (NHL) (United States). Cancer Causes Control 2002;13:965-974
8. Chang ET, Smedby KE, Hjalgrim H, et al. Medication use and risk of non-Hodgkin's lymphoma. Am J Epidemiol 2005;162:965-974
9. Zhang Y, Holford TR, Leaderer B, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004;15:419-428
10. Bernatsky S, Lee JL, Rahme E. Non-Hodgkin's lymphoma - meta-analyses of the effects of corticosteroids and non-steroidal anti-inflammatories. Rheumatology (Oxford) 2007;46:690-694
11. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006;98:51-60.
12. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006;15:2069-2077
13. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-2344
14. Thomas E, Brewster DH, Black RJ, et al. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.
15. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-1420
16. Franklin J, Lunt M, Bunn D, et al. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis 2006;65:617-622
17. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 2007;56:1433-1439
18. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
19. Baecklund E, Sundström C, Ekbom A, et al. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. Arthritis Rheum 2003;48:1543-1550
20. Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 1984;23:305-313
21. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
22. World Health Organization. World Health Organization classification of tumours: pathology and genetics of haematopoeitic and lymphoid tissues. Geneva: IARC Press, 2001.
23. Buttgereit F, Straub RH, Wehling M, et al. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50:3408-3417
24. Morand EF. Effects of glucocorticoids on inflammation and arthritis. Curr Opin Rheumatol 2007;19:302-307
25. Bernstein L, Ross RK. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Res 1992;52(19 Suppl):5510s-15s.
26. Moalli PA, Rosen ST. Glucocorticoid receptors and resistance to glucocorticoids in hematologic malignancies. Leuk Lymphoma 1994;15:363-374
27. Greenstein S, Ghias K, Krett NL, et al. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 2002;8:1681-1694
28. Zwick C, Gleissner B, Pfreundschuh M. Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma. Clin Lymphoma Myeloma 2007;8 Suppl 2:S43-9.
29. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
30. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993;36:340-347